Drug Development
Brexpiprazole as a New Serotonin–Dopamine Receptor Modulator: Considering the Clinical Relevance for Metabolic Parameters and Prolactin Levels
by Masaru Nakamura, MD, PhD, and Takahiko Nagamine, MD, PhD
September 1, 2019
No Comments
